High Prices For Biologics Abroad Serve Political Purpose In U.S. – AEI Report
The high price of biologics in overseas markets could be the result of manufacturers' political considerations in the U.S., the authors of an American Enterprise Institute/Brookings Institution working paper suggest
You may also be interested in...
Global price controls cost pharmaceutical companies approximately $18 bil. to $27 bil. a year in lost revenue, the Commerce Department maintains in a Dec. 21 report to Congress entitled "Foreign Drug Price Controls: Their Effects on R&D, Innovation and Consumer Welfare.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials